Skip to main content

Daniel Costa Comment On Regulatory Notice 22-08

I oppose limitations on leveraged an inverse products.

These products are an important part of my portfolio and are useful tools for securing my long-term financial security.

Furthermore, these don't represent an outsized risk compared to idiosyncratic risk associated with investing in (or short-sellijg) individual stocks -- yet they already carry an *abundantly clear* warning -- including both the "review" page to get more information about these ETPs as well as on the trade confirmation trade.